Opinion

Video

An Overview of the SPOTLIGHT Trial for PSMA PET in Prostate Cancer

Author(s):

Brian Helfand, MD, PhD,Brian Chapin, MD

A panel of experts introduce the SPOTLIGHT study, evaluating PSMA PET in patients with prostate cancer.

Related Videos
Jaspreet S. Sandhu, MD, answers a question during a video interview
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
Michael Jenson, PA-C, answers a question during a Zoom video interview
Couple talking with doctor | Image Credit: © Chinnapong - stock.adobe.com
Related Content
Standard pathology reports may be difficult to understand for patients with prostate cancer
January 23rd 2025

Standard pathology reports may be difficult to understand for patients with prostate cancer

Hannah Clarke
Overall, 39% of those who received a university-formatted report and 56% of those who received a VA-formatted report were able to identify that they had prostate cancer.
Dr. Murphy on increasing diversity in cancer clinical trials
February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff
In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
EU approves Mona Lisa 2.0 robotic system for prostate cancer
January 15th 2025

EU approves Mona Lisa 2.0 robotic system for prostate cancer

Hannah Clarke
The Mona Lisa 2.0 platform has been previously approved in the US, Australia, and Singapore.
Dr. Schwen on focal therapies for prostate cancer
January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic
Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.
Dual-masked PSMA-targeting T-cell engager shows promise in mCRPC
January 9th 2025

Dual-masked PSMA-targeting T-cell engager shows promise in mCRPC

Hannah Clarke
Following an initial dose of VIR-5500 of 120 µg/kg or higher, all patients achieved a PSA reduction.
Expanded indication sought for darolutamide in mHSPC in China
January 7th 2025

Expanded indication sought for darolutamide in mHSPC in China

Hannah Clarke
The application is supported by data from the pivotal phase 3 ARANOTE trial.
© 2025 MJH Life Sciences

All rights reserved.